

SPEC BUY

Current Price	\$0.63
Target Price	\$0.78

Ticker: Sector:	-	ZO.ASX hnology		
Capital Structure Shares on Issue (m) Options (m): Perf. Rights/Shares Undil. Market Cap (\$ Net Cash (\$m)*: Enterprise Value (\$ * Adj. for cap raise &		439.6 11.6 31.8 277.0 40.4 236.5		
52 wk High/Low: 12m Av Daily Vol (m):	0.64	0.25 1.55	
Key P&L				
	2H20	1H21	2H21F	
Revenue (\$m)	2.72	4.39	6.48	
Other (\$m) Expenses (\$m)	2.32 -11.93	2.46 -14.50	2.55 -15.75	
EBITDA (\$m)	-6.89	-14.50	-6.73	
NPAT (\$m)	-8.90	-9.33	0.75	
Key B/S	41120	21120	41124	
Cash (\$m)	1H20 4.52	2H20 5.81	1H21 25.88	
Receivables (\$m)	4.52 2.16	4.78	3.36	
Other Assets (\$m)	4.96	3.60	3.24	
Total Assets (\$m)	11.65	14.19	32.49	
Payables (\$m)	4.13	3.32	3.46	
Other Liab. (\$m)	1.98	6.46	6.78	
Total Liab. (\$m)	6.11	9.78	10.24	
Net Assets (\$m)	5.54	4.41	22.24	
Cash Flow (latest Qtr	s) 1Q21	2021	3Q21	
Operating (\$m)	-0.34	-2.28	-5.24	
Investing (\$m)	-0.63	-0.52	-0.37	
Financing (\$m)	3.98	19.95	0.00	
Closing Cash (\$m)	8.66	25.98	20.34	
Directors				
Peter Pawlowitsch	h Non-Exec Chairman			

Tim Levy Crispin Swan Phil Warren Matthew Stepka

Share Price Graph



Managing Director Exec. Director

Non-Exec. Director

Non-Exec. Director

Please refer to important disclosures at end of the report (from page 4)

SNAPSHOT

Financial Advisers | Stockbroking & Research | Special Situations Financing www.argonaut.com PERTH +61 8 9224 6888 HONG KONG +852 3557 4888

Wednesday, 7 July 2021

Family Zone (FZO) Backfilling projections

Analyst | Ian Christie

Quick Read

After impressive organic growth and a strategic acquisition FZO starts the financial year with 3M students on its cyber security platform, or >5% of the US student market. It provides product validation and bolsters confidence in US student growth projections. Penetration into other markets and first sales of the premium product to parents are compelling opportunities for a Company well funded post the recent \$23M cap raise.

Student penetration ahead of expectations

Market update: FZO's update this week shows strong momentum across all metrics (refer charts page 3). The June quarter, which included the acquisition of NetRef, ended with:

- 2.4M students contracted, up ~760k on the March quarter (inclusive of ~237k student licenses acquired through NetRef)
- 3.0M students on the platform inclusive of those trialling, up an impressive 1M on the March quarter (including ~450k acquired via NetRef)
- 4,129 contracted schools, after adding ~1,000 schools (including 395 acquired through NetRef)

School product validation: Inclusive of students on trials FZO now services more than 5% of the US school market. This is a significant achievement, and the rapid market penetration strongly validates the Company's cyber safety platform. With 1,473 schools and 600k students in proof-of-concept trials, we anticipate further strong conversion and growth in contracted student numbers this quarter to ~2.9M students. Further out, our current estimates assume FZO reaches 4.0M contracted students by this time next year. If achieved, this will be close to 7% of the US student market.

Family premium product: Our forecasts also assume success in penetrating the parent paid premium market, although we delay the assumed ramp up compared to our prior numbers. Given significantly higher revenue per user than school products, it contributes significantly to our longer term forecasts. Parent market penetration success in the coming year will therefore be an important de-risking event. Given the size of overseas markets we reduce emphasis on Australian and New Zealand student and parent markets.

Recommendation

The achievements through FY21 bolsters confidence in the US student market opportunity and is reflected in a lower DCF discount rate range in our valuation calculations. Forecasting risk remains high, particularly around premium product penetration and overhead cost growth, although there is also upside potential in the US and in other potential markets not captured in our numbers. We now use our FY22F closing student ARR (previously a historic number) for a multiple valuation and derive a blended target price of \$0.78 (up on \$0.61 prior). It reflects increasing confidence in FZO's potential.




Argonaut Research | www.argonaut.com

FAMILY ZONE FORECASTS		FY19A	FY20A	FY21F	FY22F	FY23F	FY24F	FY25F	FY26F
US and Australia:									
Students:									
Penetration (contracted, average for year)	%			2.4%	4.6%	6.9%	9.1%	11.2%	11.5%
Penetration (contracted, at end period)	%			3.8%	6.2%	8.3%	10.5%	11.5%	11.5%
Students (average for year)	# (m)			1.5	2.9	4.4	5.8	7.1	7.3
Students (at end period)	# (m)	0.4	0.9	2.4	4.0	5.3	6.7	7.3	7.3
Student Revenue	A\$'000's			8,469	18,905	28,964	37,888	46,381	47,739
Revenue/Student	A\$			5.49	6.43	6.57	6.52	6.49	6.53
Families									
Penetration (of Students for year)	%			1.7%	1.5%	2.7%	4.7%	8.1%	10.5%
Penetration (of Students, at end period))	%			1.4%	2.0%	3.8%	6.6%	10.5%	10.6%
Families (average for year)	# (m)			0.0	0.0	0.1	0.3	0.6	0.8
Families (at end period)	# (m)	0.0	0.0	0.0	0.1	0.2	0.4	0.8	0.8
Families Revenue	A\$'000's			1,120	2,181	7,450	18,954	44,569	63,468
Revenue/Family	A\$			43.67	50.29	62.17	69.96	76.95	82.30
Combined GP Margin	%			37%	62%	65%	68%	71%	73%

Other Income & Expenses							
Other Revenue	A\$'000's	1,181	1,800	2,000	2,000	2,000	2,000
Other Costs	A\$'000's	-630	-1,440	-1,500	-1,400	-1,400	-1,400
Other Income (incl. grants)	A\$'000's	5,000	4,000	3,000	2,000	0	0
Corporate / Fixed Costs	A\$'000's	-23,529	-27,894	-30,621	-32,782	-34,422	-36,143

roup P&L Summary									
Revenue	A\$'000's	4,185	5,090	10,770	22,886	38,414	58,842	92,949	113,206
Gross Profit	A\$'000's	2,152	2,842	4,110	13,509	24,208	39,184	65,549	82,188
GP Margin	%	51%	56%	38%	59%	63%	67%	71%	73%
Other Income / Expenses	A\$'000's	3,847	3,376	5,000	4,000	3,000	2,000	0	0
Corporate / Fixed Costs	A\$'000's	-15,800	-19,045	-23,529	-27,894	-30,621	-32,782	-34,422	-36,143
EBITDA	A\$'000's	-9,801	-12,827	-14,418	-10,385	-3,413	8,402	31,127	46,046
EBITDA Margin	%	n/a	n/a	n/a	n/a	n/a	14%	33%	41%



Annual Recurring Revenue


VALUATION TABLES


Summary		Low	High
EV/June 22F ARR (1	.2-16x)	0.81	1.04
DCF (13-11% WACC)		0.55	0.71
Average		0.68	0.88
Target Price	Low	High	Blend


Target Price	LOW	High	віепа
Valuation Range	0.68	0.88	
Weighting	50%	50%	
Target Price			0.78




Key charts (inclusive of NetRef acquisition in 4Q21)
















Students Signed Up





Financial Advisers | Stockbroking & Research | Special Situations Financing | Page 3



RESEARCH:

Ian Christie | Head of Research +61 8 9224 6872 ichristie@argonaut.com

John Macdonald | Director, Metals & Mining Research +61 8 9224 6835 jmacdonald@argonaut.com

George Ross | Analyst, Metals & Mining Research +61 8 9224 6840 georger@argonaut.com

Royce Haese | Analyst, Metals & Mining Research +61 8 9224 6869 rhaese@argonaut.com

INSTITUTIONAL SALES - PERTH:

Chris Wippl | Executive Director, Head of Institutional Sales +61 8 9224 6875 cwippl@argonaut.com

Damian Rooney | Director Institutional Sales +61 8 9224 6862 drooney@argonaut.com

John Santul | Consultant, Sales & Research +61 8 9224 6859 jsantul@argonaut.com

Josh Welch | Institutional Dealer +61 8 9224 6868 jwelch@argonaut.com

George Ogilvie | Institutional Dealer +61 8 9224 6871 gogilvie@argonaut.com

INSTITUTIONAL SALES - HONG KONG:

Damian Rooney | Director Institutional Sales +61 8 9224 6862 drooney@argonaut.com

CORPORATE AND PRIVATE CLIENT SALES:

Glen Colgan | Managing Director, Desk Manager +61 8 9224 6874 gcolgan@argonaut.com

Kevin Johnson | Executive Director, Corporate Stockbroking +61 8 9224 6880 kjohnson@argonaut.com

James McGlew | Executive Director, Corporate Stockbroking +61 8 9224 6866 jmcglew@argonaut.com

Geoff Barnesby-Johnson | Senior Dealer, Corporate Stockbroking +61 8 9224 6854 bj@argonaut.com

Ben Willoughby | Senior Dealer, Corporate Stockbroking +61 8 9224 6876 bwilloughby@argonaut.com

Philip Grant | Senior Dealer, Corporate Stockbroking +61 8 9224 6834, pgrant@argonaut.com

David Keogh | Senior Dealer, Corporate Stockbroking +61 8 9224 6852, dkeogh@argonaut.com

Rob Healy | Dealer, Private Clients +61 8 9224 6873, rhealy@argonaut.com

Cameron Prunster | Dealer, Private Clients +61 8 9224 6853 cprunster@argonaut.com

James Massey | Dealer, Private Clients +61 8 9224 6849 jmassey@argonaut.com

Chris Hill | Dealer, Private Clients +61 8 9224 6830, chill@argonaut.com

Harry Massey | Dealer, Private Clients +61 8 9224 6829, hmassey@argonaut.com

Reece O'Connell | Provisional Financial Advisor, Private Clients +61 8 9224 6851, roconnell@argonaut.com

Quinton Meyers | Provisional Financial Advisor, Private Clients +61 8 9224 6879, qmeyers@argonaut.com

Jonas Dorling | Assoc. Dealer / Prov. Fin. Advisor, Private Clients +61 8 9224 6837, jdorling@argonaut.com

Important Disclosures

Argonaut was engaged as Joint Lead Manager to the \$23M capital raising announced on 23 June 2021 and will receive fees commensurate with this service. Argonaut acted as Joint Lead Manager to the Placement that raised \$20M in October 2020 and received fees commensurate with this service.

Information Disclosure

Each research analyst of this material certifies that the views expressed in this research material accurately reflect the analyst's personal views about the subject securities and listed corporations. None of the listed corporations reviewed or any third party has provided or agreed to provide any compensation or other benefits in connection with this material to any of the analyst(s).

Snapshot Research

Valuation / Target Price: The report may or may not contain a valuation / target price.

Recommendation: If there is a valuation / target price, there will be a recommendation. In the absence of a valuation / target price, there may or may not be a recommendation. In all cases, where views / opinions are expressed, the analyst will have a reasonable basis for doing so.

Coverage: A Company is only considered formally covered when a recommendation has been provided. If coverage is to cease, this will be disclosed in a coverage update report within a suitable time period.

Research frequency: Commentary may be infrequent, ad hoc, and newsflow dependent. If the Company is not formally covered (i.e. there is no recommendation), the report may be a one-off. Recommendations and opinions should only be considered valid at the date of the report.

Risk: Where Snapshot Research is associated with a Company at an early stage of its life cycle, earnings / financial / funding risks should be considered high and investment speculative.

For U.S. persons only

This research report is a product of Argonaut Securities Pty Limited, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Argonaut Securities Pty Limited only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Argonaut Securities Pty Limited has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

Hong Kong Distribution Disclosure

This material is being distributed in Hong Kong by Argonaut Securities (Asia) Limited which is licensed (AXO 052) and regulated by the Hong Kong Securities and Futures Commission. Further information on any of the securities mentioned in this material may be obtained on request, and for this purpose, persons in the Hong Kong office should be contacted at Argonaut Securities (Asia) Limited of Unit 701, 7/F, Henley Building, 5 Queen's Road Central, Hong Kong, telephone (852) 3557 4800.

General Disclosure and Disclaimer

This research has been prepared by Argonaut Securities Pty Limited (ABN 72 108 330 650) ("ASPL") or by Argonaut Securities (Asia) Limited ("ASAL") for the use of the clients of ASPL, ASAL and other related bodies corporate (the "Argonaut Group") and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient you must not use or disclose the information in this report in any way. ASPL is a holder of an Australian Financial Services License No. 274099 and is a Market Participant of the Australian Stock Exchange Limited. ASAL has a licence (AXO 052) to Deal and Advise in Securities and Advise on Corporate Finance in Hong Kong with its activities regulated by the Securities and Futures Ordinance ("SFO") administered by the Securities and Futures Commission ("SFC") of Hong Kong.

Nothing in this report should be construed as personal financial product advice for the purposes of Section 766B of the Corporations Act 2001 (Cth). This report does not consider any of your objectives, financial situation or needs. The report may contain general financial product advice and you should therefore consider the appropriateness of the advice having regard to your situation. We recommend you obtain financial, legal and taxation advice before making any financial investment decision.

This research is based on information obtained from sources believed to be reliable and ASPL and ASAL have made every effort to ensure the information in this report is accurate, but we do not make any representation or warranty that it is accurate, reliable, complete or up to date. The Argonaut Group accepts no obligation to correct or update the information or the opinions in it. Opinions expressed are subject to change without notice and accurately reflect the analyst(s)' personal views at the time of writing. No member of the Argonaut Group or its respective employees, agents



or consultants accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research.

Nothing in this research shall be construed as a solicitation to buy or sell any financial product, or to engage in or refrain from engaging in any transaction. The Argonaut Group and/or its associates, including ASPL, ASAL, officers or employees may have interests in the financial products or a relationship with the issuer of the financial products referred to in this report by acting in various roles including as investment banker, underwriter or dealer, holder of principal positions, broker, director or adviser. Further, they may buy or sell those securities as principal or agent, and as such may effect transactions which are not consistent with the recommendations (if any) in this research. The Argonaut Group and/or its associates, including ASPL and ASAL, may receive fees, brokerage or commissions for acting in those capacities and the reader should assume that this is the case.

There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment.

The analyst(s) principally responsible for the preparation of this research may receive compensation based on ASPL's and / or ASAL's overall revenues.

Copyright

© 2021. All rights reserved. No part of this document may be reproduced or distributed in any manner without the written permission of Argonaut Securities Pty Limited and / or Argonaut Securities (Asia) Limited. Argonaut Securities Pty Limited and Argonaut Securities (Asia) Limited specifically prohibits the re-distribution of this document, via the internet or otherwise, and accepts no liability whatsoever for the actions of third parties in this respect.